FTC Chair Signals Possible Lawsuits Against Drug Companies, Continues Orange Book Probe

FTC Chair Lina Khan confirmed that the commission is exploring possible lawsuits against drug manufacturers and will continue working to stop “junk” patent listings in FDA’s Orange Book, despite a former commissioner questioning FTC’s expertise in patent law. In its announcement earlier this week that it was suing the three big pharmacy benefit managers alongside their affiliated group purchasing organization, FTC said its Bureau of Competition might also pursue legal action against drug manufacturers in future enforcement cases. When asked...